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Options for the prevention of breast cancer in carriers
of a BRCA1 or BRCA2 mutation include oophorectomy
and tamoxifen [1]. It is possible to reduce the risk of breast
cancer by 60% by performing surgical menopause at age
40 or before [2]; however, given the projected lifetime
risk of 80% and penetrance of 30% by age 40, this leaves
a residual risk post-oophorectomy of 30%. What can be
done to reduce this risk? A healthy diet should be
recommended [3] but surely it is optimistic to assume that
risk can be managed by diet alone. There is interest in
the potential use of aromatase inhibitors in chemo-
prevention, but none have yet been approved in this
setting, and their side effects have not yet been fully
evaluated. Raloxifene and tamoxifen appear to have
equivalent effects in chemoprevention in women at
average or medium risk [4], but raloxifene has not been
studied in mutation carriers. Tamoxifen has been shown
to reduce the risk of contralateral and ipsilateral breast
cancer in several studies of BRCA1 and BRCA2 carriers
[5-8]. Few would dispute that oophorectomy should be
recommended by age 40 to reduce the risk of breast and
ovarian cancer, but there is no consensus on the use of
tamoxifen – and its use is not widespread. There are some
data on the joint effect of tamoxifen and oophorectomy
in women with BRCA1 and BRCA2 mutations – this is all
based on evaluating the risks of contralateral breast
cancer. Unfortunately, we should not expect data on
primary prevention with tamoxifen any time soon.
Therefore, it is important to examine the published data
on contralateral risk.
Metcalfe et al. conducted a historical cohort study
on 491 women with a BRCA1 or BRCA2 mutation who
were followed for contralateral breast cancer [6]. The
combination of tamoxifen and oophorectomy was
particularly effective in women under 50; the hazard
ratio associated with this combination of therapy was
0.09 (95% CI, 0.01 to 0.68; P=0.02).
In a matched case-control study, Gronwald et al.
studied 285 women with bilateral breast cancer and 
a BRCA1 or BRCA2 mutation, and 751 control women
with unilateral breast cancer and a BRCA1 or BRCA2
mutation [7]. The use of tamoxifen for treating the first
breast cancer was compared between bilateral and
unilateral cases. The multivariate odds ratio for
contralateral breast cancer associated with tamoxifen use
was 0.50 for carriers of BRCA1 mutations and was 0.42
for carriers of BRCA2 mutations. However, in contrast to
Metcalfe’s study, the protective effect of tamoxifen was
not present among women who had undergone an
oophorectomy (OR=0.83). However, this subgroup was
small and the confidence interval was wide (95%CI, 
0.24-2.89). A strong protective effect of tamoxifen was
apparent among women who had undergone natural
menopause (OR=0.44; 95% CI, 0.27-0.65).
Should tamoxifen be given to women with mutations
who have had an oophorectomy? Clearly, more data
are needed. In women over 50, or who had an
oophorectomy after natural menopause, tamoxifen
should be effective. In young women (<50) following
surgical menopause, the data are less clear-cut, but I
think the drug should be considered.  Factors to take
into consideration when making this decision should
include the estimate of the residual lifetime risk of
cancer, the woman’s level of interest in mastectomy
(there is no point in giving tamoxifen to healthy women
after prophylactic mastectomy), the presence of an
intact uterus (i.e., risk of endometrial cancer) and
access to MRI screening facilities.
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